Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 53

1.

Clinical relevance of the association of interferon alfa to imatinib in chronic myeloid leukemia therapy.

Stagno F, Vigneri P, Di Raimondo F.

Int J Hematol. 2012 Jul;96(1):142-3. doi: 10.1007/s12185-012-1113-y. Epub 2012 May 26. No abstract available.

PMID:
22639055
2.

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.

O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, Lechner K, Nielsen JL, Rousselot P, Reiffers J, Saglio G, Shepherd J, Simonsson B, Gratwohl A, Goldman JM, Kantarjian H, Taylor K, Verhoef G, Bolton AE, Capdeville R, Druker BJ; IRIS Investigators.

N Engl J Med. 2003 Mar 13;348(11):994-1004.

3.

Treatment options for chronic myeloid leukemia: imatinib versus interferon versus allogeneic transplant.

Angstreich GR, Smith BD, Jones RJ.

Curr Opin Oncol. 2004 Mar;16(2):95-9. Review.

PMID:
15075898
4.

Imatinib: new preparation. For Chronic myeloid leukaemia: further assessment required.

[No authors listed]

Prescrire Int. 2003 Apr;12(64):49-52.

PMID:
12669727
5.

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.

Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML, Gathmann I, Bolton AE, van Hoomissen IC, Goldman JM, Radich JP; International Randomised Study of Interferon versus STI571 (IRIS) Study Group.

N Engl J Med. 2003 Oct 9;349(15):1423-32.

6.

Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study.

Hahn EA, Glendenning GA, Sorensen MV, Hudgens SA, Druker BJ, Guilhot F, Larson RA, O'Brien SG, Dobrez DG, Hensley ML, Cella D; IRIS Investigators.

J Clin Oncol. 2003 Jun 1;21(11):2138-46.

PMID:
12775739
7.

Imatinib activity in vitro in tumor cells from patients with chronic myeloid leukemia in chronic phase and blast crisis.

Olsson-Strömberg U, Aleskog A, Björnberg A, Höglund M, Simonsson B, Bengtsson M, Barbany G, Larsson R, Lindhagen E.

Anticancer Drugs. 2006 Jul;17(6):631-9.

PMID:
16917208
8.

Optimal initial therapy for patients with newly diagnosed chronic myeloid leukemia in chronic phase.

Atallah E, Cortes J.

Curr Opin Hematol. 2007 Mar;14(2):138-44. Review.

PMID:
17255791
9.

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.

Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MW, Silver RT, Goldman JM, Stone RM, Cervantes F, Hochhaus A, Powell BL, Gabrilove JL, Rousselot P, Reiffers J, Cornelissen JJ, Hughes T, Agis H, Fischer T, Verhoef G, Shepherd J, Saglio G, Gratwohl A, Nielsen JL, Radich JP, Simonsson B, Taylor K, Baccarani M, So C, Letvak L, Larson RA; IRIS Investigators.

N Engl J Med. 2006 Dec 7;355(23):2408-17.

10.

[Occurrence of autoimmune complications in patients with chronic myelocytic leukemia during treatment with interferon alfa].

Tóthová E, Stecová N, Kafková A, Fricová M, Svorcová E.

Vnitr Lek. 2002 May;48(5):380-3. Slovak.

PMID:
12061203
11.

Introduction of imatinib as first-line therapy for chronic myeloid leukemia in Cuba.

Morán VP, Baute RG, Facundo JC, Ramírez PH, Núñez AA, Martínez EE, Cabrera OM, Padrón CH, Otero AG, Uría JC, Estrada EE, Díaz RM, Virgil AM, Sánchez KL, Cabeza AH.

MEDICC Rev. 2011 Jan;13(1):35-40.

12.
13.
14.

Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia.

Kantarjian HM, Talpaz M, O'Brien S, Jones D, Giles F, Garcia-Manero G, Faderl S, Ravandi F, Rios MB, Shan J, Cortes J.

Blood. 2006 Sep 15;108(6):1835-40. Epub 2006 May 18.

15.
16.

Interferon alfa-2b in the treatment of chronic granulocytic leukemia.

Bergsagel DE, Haas RH, Messner HA.

Invest New Drugs. 1987;5 Suppl:S9-17.

PMID:
3298136
18.

Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment.

Hochhaus A, Druker B, Sawyers C, Guilhot F, Schiffer CA, Cortes J, Niederwieser DW, Gambacorti-Passerini C, Stone RM, Goldman J, Fischer T, O'Brien SG, Reiffers JJ, Mone M, Krahnke T, Talpaz M, Kantarjian HM.

Blood. 2008 Feb 1;111(3):1039-43. Epub 2007 Oct 11. Erratum in: Blood. 2008 Jul 15;112(2):452. Gambacorti, Carlo [corrected to Gambacorti-Passerini, Carlo].

19.

The role of interferon-alpha in the treatment of chronic myeloid leukemia.

Kujawski LA, Talpaz M.

Cytokine Growth Factor Rev. 2007 Oct-Dec;18(5-6):459-71. Epub 2007 Aug 20. Review.

PMID:
17703986
20.

Supplemental Content

Support Center